- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Genome Wide Association Study.
Displaying page 1 of 1.
EudraCT Number: 2013-001141-14 | Sponsor Protocol Number: GV28855 | Start Date*: 2013-10-01 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIV... | |||||||||||||
Medical condition: Chronic liver disease caused by the hepatitis B virus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) BG (Completed) IT (Completed) GR (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004824-77 | Sponsor Protocol Number: 27UCS2015 | Start Date*: 2016-06-23 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in resected stage I-III colorectal ... | |||||||||||||
Medical condition: Surgical resected colorectal cancer (stage I-III) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000815-15 | Sponsor Protocol Number: BOS-1168-WEI-0080-I | Start Date*: 2011-08-02 |
Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen | ||
Full Title: BOSTRIP (Investigator Initiated Trial) (Biomarkers of systemic treatment response in Psoriasis) Differential analysis of metabolomic profiles in patients with chronic plaque psoriasis underg... | ||
Medical condition: Psoriasis is a chronic hyperproliferative and inflammatory skin disease with its major subtype, chronic plaque-type psoriasis, affecting approximately 2% of individuals in Western populations. It m... | ||
Disease: | ||
Population Age: Elderly | Gender: | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002625-35 | Sponsor Protocol Number: CALGB80802 | Start Date*: 2013-09-23 |
Sponsor Name:All Ireland Co-operative Oncology Research Group (ICORG) | ||
Full Title: Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC) | ||
Medical condition: Advanced or Metastatic Hepatocellular Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002387-32 | Sponsor Protocol Number: UoL001019 | Start Date*: 2014-08-05 | |||||||||||||||||||||
Sponsor Name:University of Liverpool | |||||||||||||||||||||||
Full Title: Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis | |||||||||||||||||||||||
Medical condition: Aminoglycoside-induced nephrotoxicity | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002917-30 | Sponsor Protocol Number: CARCINOSIS | Start Date*: 2015-09-10 | ||||||||||||||||
Sponsor Name:Medical University of Vienna | ||||||||||||||||||
Full Title: Assessment of histopathological response to combination chemotherapy with Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in patients with peritoneal metastasis from colorectal cancer (CARCIN... | ||||||||||||||||||
Medical condition: Patients with peritoneal carcinomatosis from colorectal cancer are treated with a combination chemotherapy (FOLFOXIRI+ Bevacizumab) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004982-37 | Sponsor Protocol Number: NBK155/1/2020 | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:MEDICAL UNIVERSITY OF GDAŃSK | |||||||||||||
Full Title: Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome | |||||||||||||
Medical condition: NEPHROTIC SYNDROME | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005531-13 | Sponsor Protocol Number: MED3-201401 | Start Date*: 2015-11-26 |
Sponsor Name:Univerity of Bonn | ||
Full Title: Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, ... | ||
Medical condition: Chronic Phase Chronic myelogenous leukaemia( CP-CML) patients who either developed intolerance or treatment failure to previous Imatinib, Dasatinib or Nilotinib as 1st or 2nd line therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-000368-90 | Sponsor Protocol Number: 218MS205 | Start Date*: 2012-08-08 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and ... | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005386-35 | Sponsor Protocol Number: GI-4000-02 | Start Date*: 2008-10-07 | |||||||||||
Sponsor Name:GlobeImmune, Inc. | |||||||||||||
Full Title: A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant... | |||||||||||||
Medical condition: Pancreatic Cancer, post resection R0/R1 status, with tumor sequence confirmation of Ras mutations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001636-22 | Sponsor Protocol Number: TROPICALACS | Start Date*: 2013-08-26 | |||||||||||
Sponsor Name:Hospital of the University of Munich, Grosshadern | |||||||||||||
Full Title: A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrom... | |||||||||||||
Medical condition: Troponin positive acute coronary syndrome after successful percutaneous coronary intervention with an indication for a standard treatment of 12 month with prasugrel | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) AT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001271-16 | Sponsor Protocol Number: AGO-OVAR28 | Start Date*: 2022-08-01 | |||||||||||||||||||||
Sponsor Name:AGO Research GmbH | |||||||||||||||||||||||
Full Title: Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) | |||||||||||||||||||||||
Medical condition: Patients with newly diagnosed, histologically confirmed, primary advanced invasive high grade epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer, FIGO stage III/IV (except FIGO ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.